<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAW</journal-id>
<journal-id journal-id-type="hwp">sptaw</journal-id>
<journal-title>Therapeutic Advances in Drug Safety</journal-title>
<issn pub-type="ppub">2042-0986</issn>
<issn pub-type="epub">2042-0994</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042098613490009</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042098613490009</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A study on drug–drug interactions through prescription analysis in a South Indian teaching hospital</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kulkarni</surname><given-names>Vijay</given-names></name>
<aff id="aff1-2042098613490009">JSS College of Pharmacy (A Constituent College of JSS University) Post Box No.20, Ooty – 643 001 Tamil Nadu, India</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Bora</surname><given-names>Swathi Swaroopa</given-names></name>
<aff id="aff2-2042098613490009">JSS College of Pharmacy - Pharmacy Practice, Rocklands, Ooty, Tamil Nadu, India</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Sirisha</surname><given-names>Sapineni</given-names></name>
<aff id="aff3-2042098613490009">JSS College of Pharmacy - Pharmacy Practice, Rocklands, Ooty, Tamil Nadu, India</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Saji</surname><given-names>Mohammed</given-names></name>
<aff id="aff4-2042098613490009">JSS College of Pharmacy - Pharmacy Practice, Rocklands, Ooty, Tamil Nadu, India</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Sundaran</surname><given-names>Siraj</given-names></name>
<aff id="aff5-2042098613490009">JSS College of Pharmacy - Pharmacy Practice, Rocklands, Ooty, Tamil Nadu, India</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042098613490009"><email>sirajsundaran@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>141</fpage>
<lpage>146</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-2042098613490009">
<title>Objective:</title>
<p>The objective of this study was to assess the drug–drug interactions (DDIs) through prescription analysis among the inpatients of a South Indian teaching hospital.</p>
</sec>
<sec id="section2-2042098613490009">
<title>Methods:</title>
<p>The study was a prospective observational prescription analysis conducted for a period of 6 months, from October 2010 to March 2011. The prescriptions having two or more drugs and where a DDI was suspected were selected by the physician in charge of the ward. The drugs in the prescription were then entered into the drug interaction checker software. The DDIs were classified based on the mechanism of interactions, severity of interactions, relation to the number of drugs prescribed, and disease conditions were also determined.</p>
</sec>
<sec id="section3-2042098613490009">
<title>Results:</title>
<p>A total of 204 prescriptions were analyzed, of which 186 prescriptions had 856 DDIs. Most of the DDIs were pharmacokinetic drug interactions (42%) followed by unknown mechanisms (34%) and pharmacodynamic mechanisms (24%). The study findings showed that the prescriptions for cardiovascular with respiratory disease conditions had the greatest number of drug interactions on average. A severity assessment showed that majority of the DDIs were moderate (70%) followed by minor (28%). The study results showed that as the number of drugs increases in a prescription, the number of DDIs also increases. The interventions determined showed that dosage adjustment (12%) was to be followed in most of the DDIs.</p>
</sec>
<sec id="section4-2042098613490009">
<title>Conclusion:</title>
<p>This study assists in understanding the factors associated with DDIs that can help in safe and effective use of drugs in the future.</p>
</sec>
</abstract>
<kwd-group>
<kwd>disease conditions</kwd>
<kwd>drug–drug interaction</kwd>
<kwd>inpatients</kwd>
<kwd>management</kwd>
<kwd>mechanism</kwd>
<kwd>severity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-2042098613490009" sec-type="intro">
<title>Introduction</title>
<p>A drug–drug interaction (DDI) is defined as a pharmacokinetic or pharmacodynamic influence of drugs on each other, which may result in desired effects, in reduced efficacy and effectiveness or increased toxicity [<xref ref-type="bibr" rid="bibr18-2042098613490009">Schalekamp, 1997</xref>]. DDIs may lead to adverse drug reactions that can be severe enough to necessitate hospitalization. Studies have shown that DDIs may cause up to 3% of all hospital admissions [<xref ref-type="bibr" rid="bibr11-2042098613490009">Huic <italic>et al.</italic> 1994</xref>; <xref ref-type="bibr" rid="bibr12-2042098613490009">Jankel and Fitterman, 1993</xref>; <xref ref-type="bibr" rid="bibr16-2042098613490009">McDonnell and Jacobs, 2002</xref>]. Approximately 37–60% of patients admitted to hospital may have one or more potentially interacting drug combinations at admission [<xref ref-type="bibr" rid="bibr4-2042098613490009">Costa, 1991</xref>; <xref ref-type="bibr" rid="bibr8-2042098613490009">Gosney and Tallis, 1984</xref>; <xref ref-type="bibr" rid="bibr15-2042098613490009">Manchon <italic>et al.</italic> 1989</xref>; <xref ref-type="bibr" rid="bibr17-2042098613490009">Mitchell <italic>et al.</italic> 1979</xref>; <xref ref-type="bibr" rid="bibr19-2042098613490009">Schneider <italic>et al.</italic> 1992</xref>; <xref ref-type="bibr" rid="bibr21-2042098613490009">Shinn <italic>et al.</italic> 1983</xref>]. In inpatients, the risk of having potentially interacting drug combinations can additionally increase because new drugs are often added to the existing drug therapy [<xref ref-type="bibr" rid="bibr9-2042098613490009">Heininger-Rothbucher <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr10-2042098613490009">Herr <italic>et al.</italic> 1992</xref>; <xref ref-type="bibr" rid="bibr24-2042098613490009">Wiesner <italic>et al.</italic> 1999</xref>]. DDIs are a concern for patients and providers, as polypharmacy is becoming more common in managing complex diseases or comorbidities and the consequences can range from untoward effects to drug-related morbidity and mortality [<xref ref-type="bibr" rid="bibr13-2042098613490009">Juurlink <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr16-2042098613490009">McDonnell and Jacobs, 2002</xref>]. Healthcare professionals’ ability to recognize potential DDIs is important in reducing their potential risks and adverse consequences [<xref ref-type="bibr" rid="bibr14-2042098613490009">Ko <italic>et al.</italic> 2008</xref>]. The assessment of prevalence and patients at risk for clinically important DDIs at visit will be useful in minimizing medication-related problems and improving pharmaceutical care [<xref ref-type="bibr" rid="bibr1-2042098613490009">Aparasu <italic>et al.</italic> 2007</xref>]. The potential benefits of drug combinations should be weighed against the seriousness of the DDI, taking into account the availability of alternatives. If the benefit of treatment is of such importance that it outweighs the potential risks, and no safer alternatives are apparent, then the risks of a potential DDI may be tolerated and treatment continued [<xref ref-type="bibr" rid="bibr2-2042098613490009">Becker <italic>et al.</italic> 2007</xref>].</p>
<p>The objectives of the study included the following: categorization of DDIs in the prescriptions based on the mechanism involved; determination of the severity of DDIs in the prescriptions; determination of the relationship between the number of drugs in the prescription and its potential for DDIs; determination of the potential for DDIs with different diagnoses; determination of the intervention control for various DDIs observed.</p>
</sec>
<sec id="section6-2042098613490009" sec-type="methods">
<title>Methods</title>
<p>The study was conducted in the South Indian teaching hospital. On average 180 outpatients and 20 inpatients were admitted per day for consultation and treatment, respectively. The hospital had various wards such as an intensive care unit, medical wards, surgical wards, pediatric wards and gynecology department. The prospective observational prescription analysis study was conducted for a period of 6 months from October 2010 to March 2011. The prescriptions from the inpatient medical wards including male and female medical wards, pediatrics ward and intensive care unit were used for the study. The study was approved by the Institutional Ethic Committee, JSS College of Pharmacy, Ooty. Inpatients with two or more drugs in their daily prescriptions were included in the study and patients with a history of drug abuse and surgical patient prescriptions were excluded from the study.</p>
<p>Patient case sheets, patient medical records and a DDI documentation form were used. A drug interaction check was performed using the <ext-link ext-link-type="uri" xlink:href="http://www.drugs.com">www.drugs.com</ext-link> database; this is powered by four independent leading medical-information suppliers: Wolters Kluwer Health, American Society of Health-System Pharmacists, Cerner Multum and Thomson Reuters Micromedex. According to this tool, drug interactions are categorized as minor, moderate or major which indicates the possible risks of occurrence of DDIs which can occur in patients, but not the actual severity of DDI.</p>
<p>The initial part of the study was designed to provide awareness about DDIs and their impact on healthcare professionals such as doctors, nurses, pharmacists, laboratory technicians, nursing students and pharmacy students. A DDI documentation form was prepared according to the data requirement for the study which included information such as patient details, diagnosis, drugs prescribed, drug interaction mechanism categorization, consequences and severity, and required management.</p>
<p>The case sheets that had two or more drugs in the prescription were selected by the clinical pharmacist. Among these selected case sheets, the physician chose 204 prescriptions where he or she expected a DDI. After the prescription selection by the physician in charge, the relevant data from the prescription were entered into the DDI documentation form. The drugs in the prescription were further entered into the drug interaction checker on <ext-link ext-link-type="uri" xlink:href="http://www.drugs.com">www.drugs.com</ext-link> and any DDIs in the prescription of the patients were assessed. The data obtained was used to categorize interactions based on the mechanism as pharmacokinetic or pharmacodynamic. The pharmacokinetic drug interactions were further categorized into interactions based on absorption, distribution, metabolism and elimination. The severities of the interactions were assessed and categorized as major (can cause permanent damage or life risk), moderate (can cause harm and treatment is required) or minor (can cause small or no clinical effect, with no treatment required). The relationship between the number of drugs in the prescription and the potential for drug interactions was also assessed. The drugs prescribed for disease conditions which were most prone to DDIs, and the age groups of the patients where DDIs were common were also assessed.</p>
<sec id="section7-2042098613490009">
<title>Statistical analysis</title>
<p>Statistical analysis was performed using Epi Info 2002 statistical software. Differences were considered statistically significant for <italic>p</italic> values &lt;0.05.</p>
</sec>
</sec>
<sec id="section8-2042098613490009" sec-type="results">
<title>Results</title>
<p>A total of 204 prescriptions were analyzed during the study period, of which 186 (91%) prescriptions showed 856 DDIs. The study prescriptions comprised 42% pharmacokinetic DDIs, 34% were by an unknown mechanism and 24% were pharmacodynamic DDIs (<xref ref-type="table" rid="table1-2042098613490009">Table 1</xref>). Statistical analysis showed a significant difference within the different pharmacokinetic DDIs, where drug interaction due to altered metabolism occurred most often (19%) followed by absorption-related drug interaction (16%) then interaction-related elimination changes (7%).</p>
<table-wrap id="table1-2042098613490009" position="float">
<label>Table 1.</label>
<caption>
<p>Categorization of drug–drug interactions based on mechanism.</p>
</caption>
<graphic alternate-form-of="table1-2042098613490009" xlink:href="10.1177_2042098613490009-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mechanism</th>
<th align="left">Number of interactions (<italic>n</italic> = 856)</th>
<th align="left">Percentage</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacokinetic drug-drug interactions</td>
<td><bold>361</bold></td>
<td><bold>42</bold></td>
<td>–</td>
</tr>
<tr>
<td>Absorption</td>
<td>135</td>
<td>16</td>
<td/>
</tr>
<tr>
<td>Distribution</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>Metabolism</td>
<td>166</td>
<td>19</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Excretion</td>
<td>57</td>
<td>7</td>
<td/>
</tr>
<tr>
<td>Pharmacodynamic drug-drug interactions</td>
<td>206</td>
<td>24</td>
<td>–</td>
</tr>
<tr>
<td>Unknown mechanism</td>
<td>289</td>
<td>34</td>
<td>–</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>There was a greater number of moderate DDIs than minor or major interactions (602 <italic>versus</italic> 241 or 13, respectively, <italic>p</italic> &lt; 0.05; <xref ref-type="table" rid="table2-2042098613490009">Table 2</xref>).</p>
<table-wrap id="table2-2042098613490009" position="float">
<label>Table 2.</label>
<caption>
<p>Categorization of drug–drug interactions based on severity.</p>
</caption>
<graphic alternate-form-of="table2-2042098613490009" xlink:href="10.1177_2042098613490009-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Severity</th>
<th align="left">Number of drug interactions (<italic>n</italic> = 856)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>13 (2%)</td>
</tr>
<tr>
<td>Moderate</td>
<td>602 (70%)<xref ref-type="table-fn" rid="table-fn1-2042098613490009">*</xref></td>
</tr>
<tr>
<td>Minor</td>
<td>241 (28%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2042098613490009">
<label>*</label>
<p><italic>p</italic> value &lt;0.05 compared with moderate or minor drug interactions.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Prescriptions for patients with cardiovascular and respiratory disease conditions led to the greatest average number of DDIs (7.33/patient), followed by cardiovascular disease prescriptions (6.34/patient) then hepatic disease prescriptions (6.00/patient); see <xref ref-type="table" rid="table3-2042098613490009">Table 3</xref>.</p>
<table-wrap id="table3-2042098613490009" position="float">
<label>Table 3.</label>
<caption>
<p>Drug–drug interactions based on organ system disorders.</p>
</caption>
<graphic alternate-form-of="table3-2042098613490009" xlink:href="10.1177_2042098613490009-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Organ system disorder</th>
<th align="left">Number of drug interactions (<italic>n</italic> = 856)</th>
<th align="left">Number of patients (<italic>n</italic> = 186)</th>
<th align="left">Average number of drug–drug interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular and respiratory system</td>
<td>66 (8%)</td>
<td>9</td>
<td>7.33</td>
</tr>
<tr>
<td>Cardiovascular system</td>
<td>279 (33%)</td>
<td>44</td>
<td>6.34</td>
</tr>
<tr>
<td>Hepatic system</td>
<td>12 (1%)</td>
<td>2</td>
<td>6.00</td>
</tr>
<tr>
<td>Renal system</td>
<td>10 (1%)</td>
<td>2</td>
<td>5.00</td>
</tr>
<tr>
<td>Respiratory system</td>
<td>164 (19%)</td>
<td>33</td>
<td>4.97</td>
</tr>
<tr>
<td>Respiratory and endocrine system</td>
<td>4 (1%)</td>
<td>1</td>
<td>4.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>95 (11%)</td>
<td>24</td>
<td>3.96</td>
</tr>
<tr>
<td>Gastrointestinal system</td>
<td>56 (7 %)</td>
<td>15</td>
<td>3.73</td>
</tr>
<tr>
<td>Hematology</td>
<td>11 (1%)</td>
<td>3</td>
<td>3.67</td>
</tr>
<tr>
<td>Endocrine system</td>
<td>28 (3%)</td>
<td>8</td>
<td>3.50</td>
</tr>
<tr>
<td>Others</td>
<td>70 (7%)</td>
<td>21</td>
<td>3.33</td>
</tr>
<tr>
<td>Cardiovascular and hematology</td>
<td>3 (1%)</td>
<td>1</td>
<td>3.00</td>
</tr>
<tr>
<td>Infectious disease</td>
<td>56 (6%)</td>
<td>22</td>
<td>2.55</td>
</tr>
<tr>
<td>Gastrointestinal and alcoholic liver disease</td>
<td>2 (1%)</td>
<td>1</td>
<td>2.00</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results showed that when the number of drugs increased in a prescription, the number of DDIs also increased (<xref ref-type="table" rid="table4-2042098613490009">Table 4</xref>).</p>
<table-wrap id="table4-2042098613490009" position="float">
<label>Table 4.</label>
<caption>
<p>Number of drug interactions per patient.</p>
</caption>
<graphic alternate-form-of="table4-2042098613490009" xlink:href="10.1177_2042098613490009-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Number of drugs</th>
<th align="left">Number of patients (<italic>n</italic> = 186)</th>
<th align="left">Number of drug interactions (<italic>n</italic> = 856)</th>
<th align="left">Average number of drug–drug interactions with number of drugs in the prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–5</td>
<td>35</td>
<td>78 (9%)</td>
<td>2.23</td>
</tr>
<tr>
<td>6–10</td>
<td>146</td>
<td>731 (85%)</td>
<td>5.01</td>
</tr>
<tr>
<td>&gt;10</td>
<td>5</td>
<td>47 (6%)</td>
<td>9.40</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The drug interaction software showed that dosage adjustment was the most popular intervention following a DDI (102 of 856 cases; <xref ref-type="table" rid="table5-2042098613490009">Table 5</xref>).</p>
<table-wrap id="table5-2042098613490009" position="float">
<label>Table 5.</label>
<caption>
<p>Management requirements for the drug–drug interactions documented.</p>
</caption>
<graphic alternate-form-of="table5-2042098613490009" xlink:href="10.1177_2042098613490009-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Management</th>
<th align="left">Number of drug–drug interactions (<italic>n</italic> = 856)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage adjustment</td>
<td>102 (12%)</td>
</tr>
<tr>
<td>No management required</td>
<td>94 (11%)</td>
</tr>
<tr>
<td>Monitor for signs and symptoms</td>
<td>93 (11%)</td>
</tr>
<tr>
<td>Monitor for drug levels</td>
<td>79 (9%)</td>
</tr>
<tr>
<td>Monitor for biochemical parameters</td>
<td>74 (9 %)</td>
</tr>
<tr>
<td>Change dosing interval</td>
<td>64 (8%)</td>
</tr>
<tr>
<td>Avoid the combination</td>
<td>62 (7%)</td>
</tr>
<tr>
<td>Monitor for electrolyte levels</td>
<td>60 (7%)</td>
</tr>
<tr>
<td>Monitor for patient response</td>
<td>54 (6%)</td>
</tr>
<tr>
<td>Monitor for signs and symptoms and biochemical parameters</td>
<td>42 (5%)</td>
</tr>
<tr>
<td>Monitor for serum creatinine levels</td>
<td>41 (4%)</td>
</tr>
<tr>
<td>Dose titration</td>
<td>28 (3%)</td>
</tr>
<tr>
<td>Monitor for signs and symptoms and drug level</td>
<td>23 (3 %)</td>
</tr>
<tr>
<td>Monitor for patient response and dose adjustment</td>
<td>17 (2%)</td>
</tr>
<tr>
<td>Monitor for drug level and biochemical parameters</td>
<td>13 (2%)</td>
</tr>
<tr>
<td>Monitor for electrolyte and drug level</td>
<td>10 (1%)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section9-2042098613490009" sec-type="discussion">
<title>Discussion</title>
<p>Our study found that among the 856 interactions, 42% were pharmacokinetic DDIs, 24% were pharmacodynamic DDIs and 34% involved unknown mechanisms. These findings were different from another study reported in the literature where the discharge medications of the inpatients were of concern and pharmacodynamic DDIs were dominant [<xref ref-type="bibr" rid="bibr6-2042098613490009">Egger <italic>et al.</italic> 2003</xref>].</p>
<p>The severity assessment of DDIs in our study showed that most of the interactions were moderate (70%) followed by minor (28%) and major (2%) interactions. This trend is similar to that found in another report [<xref ref-type="bibr" rid="bibr5-2042098613490009">Dambro and Kallgren, 1988</xref>].</p>
<p>Our study found that the average number of DDIs per patient increased as the number of drugs in the prescription increased. This finding was similar to another published report where the potential for a drug interaction increased from 13% to 82% as the number of medications increased from 2 to 7 or more [<xref ref-type="bibr" rid="bibr7-2042098613490009">Goldberg <italic>et al.</italic> 1996</xref>].</p>
<p>We found that prescriptions for patients with cardiovascular disease with comorbid conditions led to the greatest average number of drug interactions, followed by cardiovascular disease (without comorbid conditions). This result is similar to the finding obtained from another study where cardiovascular disease prescriptions had a relatively high risk of drug interactions [<xref ref-type="bibr" rid="bibr7-2042098613490009">Goldberg <italic>et al.</italic> 1996</xref>].</p>
<p>The most common management plan found in our study for most of the DDIs was dose adjustments; this is similar to the results reported by Bergk and colleagues [<xref ref-type="bibr" rid="bibr3-2042098613490009">Bergk <italic>et al.</italic> 2004</xref>].</p>
<p>The significance of using electronic software has been reported in the literature [<xref ref-type="bibr" rid="bibr22-2042098613490009">Taegtmeyer <italic>et al.</italic> 2012</xref>]. The authors found that checks by a pharmacologist agreed with only 11% of DDI alerts from electronic software, and the remaining 89% were not thought clinically relevant. Our study showed the same finding. Waring and McGettigan stated that the occurrence of adverse effects is more difficult to detect for newer drugs, where there is less clinical experience and fewer data, emphasizing the role for clinical interpretation [<xref ref-type="bibr" rid="bibr23-2042098613490009">Waring and McGettigan, 2011</xref>]. The result obtained in our study was based on the classification as minor, moderate or major according the interaction checker that was used. Sepehri and colleagues used a similar software detection approach, and found the occurrence of DDIs in 20% of patients [<xref ref-type="bibr" rid="bibr20-2042098613490009">Sepehri <italic>et al.</italic> 2012</xref>].</p>
</sec>
<sec id="section10-2042098613490009" sec-type="conclusions">
<title>Conclusion</title>
<p>Our study helped in understanding about the most prone age groups, disease conditions, and the common mechanisms that can cause DDIs in inpatient prescriptions. This may help in improving the safe and effective use of drugs in our hospital. The use of the drug interaction checker software has greatly aided our study by assessing the findings mentioned above more easily; this would have been harder to achieve if done manually. Our study also helped to define the significant role of the pharmacist in assessing and controlling DDIs. Further research may include an evaluation of the economic, clinical, and humanistic outcomes of clinically important DDIs, especially among those at risk.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aparasu</surname><given-names>R.</given-names></name>
<name><surname>Baer</surname><given-names>R.</given-names></name>
<name><surname>Aparasu</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Clinically important potential drug–drug interactions in outpatient settings</article-title>. <source>Res Social Admin Pharm</source> <volume>3</volume>: <fpage>426</fpage>.</citation>
</ref>
<ref id="bibr2-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Becker</surname><given-names>M.</given-names></name>
<name><surname>Caspers</surname><given-names>P.</given-names></name>
<name><surname>Kallewaard</surname><given-names>M.</given-names></name>
<name><surname>Bruinink</surname><given-names>R.</given-names></name>
<name><surname>Kylstra</surname><given-names>N.</given-names></name>
<name><surname>Heisterkamp</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Determinants of potential drug–drug interaction associated dispensing in community pharmacies in the Netherlands</article-title>. <source>Pharm World Sci</source> <volume>29</volume>(<issue>2</issue>): <fpage>51</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr3-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergk</surname><given-names>V.</given-names></name>
<name><surname>Gasse</surname><given-names>C.</given-names></name>
<name><surname>Rothenbacher</surname><given-names>D.</given-names></name>
<name><surname>Loew</surname><given-names>M.</given-names></name>
<name><surname>Brenner</surname><given-names>H.</given-names></name>
<name><surname>Haefeli</surname><given-names>W.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Drug interactions in primary care: Impact of a new algorithm on risk determination</article-title>. <source>Clin Pharmacol Therapeut</source> <volume>76</volume>: <fpage>85</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr4-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.J.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Potential drug interactions in an ambulatory geriatric population</article-title>. <source>Fam Practice</source> <volume>8</volume>: <fpage>234</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr5-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dambro</surname><given-names>M.</given-names></name>
<name><surname>Kallgren</surname><given-names>M.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Drug interactions in a clinic using COSTAR</article-title>. <source>Comput Biol Med</source> <volume>18</volume>: <fpage>31</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr6-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Egger</surname><given-names>S.</given-names></name>
<name><surname>Drewe</surname><given-names>J.</given-names></name>
<name><surname>Schlienger</surname><given-names>R.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Potential drug–drug interactions in the medication of medical patients at hospital discharge</article-title>. <source>Eur J Clin Pharmacol</source> <volume>58</volume>(<issue>11</issue>): <fpage>773</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr7-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>R.M.</given-names></name>
<name><surname>Mabee</surname><given-names>J.</given-names></name>
<name><surname>Chan</surname><given-names>L.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population</article-title>. <source>Am J Emerg Med</source> <volume>14</volume>: <fpage>447</fpage>–<lpage>450</lpage>.</citation>
</ref>
<ref id="bibr8-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gosney</surname><given-names>M.</given-names></name>
<name><surname>Tallis</surname><given-names>R.</given-names></name>
</person-group> (<year>1984</year>) <article-title>Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital</article-title>. <source>Lancet</source> <volume>324</volume>: <fpage>564</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr9-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heininger-Rothbucher</surname><given-names>D.</given-names></name>
<name><surname>Bischinger</surname><given-names>S.</given-names></name>
<name><surname>Ulmer</surname><given-names>H.</given-names></name>
<name><surname>Pechlaner</surname><given-names>C.</given-names></name>
<name><surname>Speer</surname><given-names>G.</given-names></name>
<name><surname>Wiedermann</surname><given-names>C.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Incidence and risk of potential adverse drug interactions in the emergency room</article-title>. <source>Resuscitation</source> <volume>49</volume>: <fpage>283</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr10-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herr</surname><given-names>R.</given-names></name>
<name><surname>Caravati</surname><given-names>E.</given-names></name>
<name><surname>Tyler</surname><given-names>L.</given-names></name>
<name><surname>Iorg</surname><given-names>E.</given-names></name>
<name><surname>Linscott</surname><given-names>M.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Prospective evaluation of adverse drug interactions in the emergency department</article-title>. <source>Ann Emerg Med</source> <volume>21</volume>: <fpage>1331</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr11-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huic</surname><given-names>M.</given-names></name>
<name><surname>Mucolic</surname><given-names>V.</given-names></name>
<name><surname>Vrhovac</surname><given-names>B.</given-names></name>
<name><surname>Francetic</surname><given-names>I.</given-names></name>
<name><surname>Bakran</surname><given-names>I.</given-names></name>
<name><surname>Giljanovic</surname><given-names>S.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Adverse drug reactions resulting in hospital admission</article-title>. <source>Int J Clin Pharmacol Therapeut</source> <volume>32</volume>: <fpage>675</fpage>.</citation>
</ref>
<ref id="bibr12-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jankel</surname><given-names>C.</given-names></name>
<name><surname>Fitterman</surname><given-names>L.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Epidemiology of drug–drug interactions as a cause of hospital admissions</article-title>. <source>Drug Safety</source> <volume>9</volume>: <fpage>51</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr13-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juurlink</surname><given-names>D.</given-names></name>
<name><surname>Mamdani</surname><given-names>M.</given-names></name>
<name><surname>Kopp</surname><given-names>A.</given-names></name>
<name><surname>Laupacis</surname><given-names>A.</given-names></name>
<name><surname>Redelmeier</surname><given-names>D.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Drug–drug interactions among elderly patients hospitalized for drug toxicity</article-title>. <source>JAMA</source> <volume>289</volume>: <fpage>1652</fpage>–<lpage>1658</lpage>.</citation>
</ref>
<ref id="bibr14-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ko</surname><given-names>Y.</given-names></name>
<name><surname>Malone</surname><given-names>D.</given-names></name>
<name><surname>D’Agostino</surname><given-names>J.</given-names></name>
<name><surname>Skrepnek</surname><given-names>G.</given-names></name>
<name><surname>Armstrong</surname><given-names>E.</given-names></name>
<name><surname>Brown</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Potential determinants of prescribers’ drug–drug interaction knowledge</article-title>. <source>Res Social Admin Pharm</source> <volume>4</volume>: <fpage>355</fpage>–<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr15-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manchon</surname><given-names>N.</given-names></name>
<name><surname>Bercoff</surname><given-names>E.</given-names></name>
<name><surname>Lemarchand</surname><given-names>P.</given-names></name>
<name><surname>Chassagne</surname><given-names>P.</given-names></name>
<name><surname>Senant</surname><given-names>J.</given-names></name>
<name><surname>Bourreille</surname><given-names>J.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Incidence and severity of drug interactions in the elderly: a prospective study of 639 patients]</article-title>. <source>Rev Méd Interne Fond Soc Natl Fr Méd Interne</source> <volume>10</volume>: <fpage>521</fpage>.</citation>
</ref>
<ref id="bibr16-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonnell</surname><given-names>P.</given-names></name>
<name><surname>Jacobs</surname><given-names>M.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Hospital admissions resulting from preventable adverse drug reactions</article-title>. <source>Ann Pharmacother</source> <volume>36</volume>: <fpage>1331</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr17-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>G.</given-names></name>
<name><surname>Stanaszek</surname><given-names>W.</given-names></name>
<name><surname>Nichols</surname><given-names>N.</given-names></name>
</person-group> (<year>1979</year>) <article-title>Documenting drug–drug interactions in ambulatory patients</article-title>. <source>Am J Health-Syst Pharm</source> <volume>36</volume>: <fpage>653</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr18-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schalekamp</surname><given-names>T.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Omgaan met geneesmiddeleninteracties</article-title>. <source>Geneesmiddelenbulletin</source> <volume>31</volume>(<issue>8</issue>): <fpage>87</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr19-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>J.</given-names></name>
<name><surname>Mion</surname><given-names>L.</given-names></name>
<name><surname>Frengley</surname><given-names>J.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Adverse drug reactions in an elderly outpatient population</article-title>. <source>Am J Health-Syst Pharm</source> <volume>49</volume>: <fpage>90</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr20-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sepehri</surname><given-names>G.</given-names></name>
<name><surname>Khazaelli</surname><given-names>P.</given-names></name>
<name><surname>Dahooie</surname><given-names>F.</given-names></name>
<name><surname>Sepehri</surname><given-names>E.</given-names></name>
<name><surname>Dehghani</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Prevalence of potential drug interactions in an Iranian general hospital</article-title>. <source>Indian J Pharmaceut Sci</source> <volume>74</volume>: <fpage>75</fpage>.</citation>
</ref>
<ref id="bibr21-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shinn</surname><given-names>A.</given-names></name>
<name><surname>Shrewsbury</surname><given-names>R.</given-names></name>
<name><surname>Anderson</surname><given-names>K.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Development of a computerized drug interaction database (Medicomsm) for use in a patient specific environment</article-title>. <source>Drug Inform J</source> <volume>17</volume>: <fpage>205</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr22-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taegtmeyer</surname><given-names>A.</given-names></name>
<name><surname>Kullak-Ublick</surname><given-names>G.</given-names></name>
<name><surname>Widmer</surname><given-names>N.</given-names></name>
<name><surname>Falk</surname><given-names>V.</given-names></name>
<name><surname>Jetter</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Clinical usefulness of electronic drug–drug interaction checking in the care of cardiovascular surgery inpatients</article-title>. <source>Cardiology</source> <volume>123</volume>: <fpage>219</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr23-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waring</surname><given-names>W.</given-names></name>
<name><surname>McGettigan</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Clinical toxicology and drug regulation: a United Kingdom perspective</article-title>. <source>Clin Toxicol</source> <volume>49</volume>: <fpage>452</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr24-2042098613490009">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiesner</surname><given-names>C.</given-names></name>
<name><surname>Hersberger</surname><given-names>K.</given-names></name>
<name><surname>Surber</surname><given-names>C.</given-names></name>
<name><surname>Haefeli</surname><given-names>W.</given-names></name>
</person-group>(<year>1999</year>) <article-title>Drug safety after hospital discharge</article-title>. <source>Pharm World Sci</source> <volume>22</volume>: <fpage>A18</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>